Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib open-label extension for immune dysregulation in primary immunodeficiency
2025-522444-40-00Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of leniolisib in Immunogenetic disorder, sponsored by Pharming Group. Primary endpoint: Adverse events and overall safety. Started Feb 2026; status: completed.
02
Drugs
leniolisib
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2025-522444-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522444-40-00.